The era of competing on cost and compliance alone is over. As India solidifies its role as the “Pharmacy of the World,” a new, decisive battleground has emerged: the sustainable supply chain. With the industry on track to hit $92 billion by 2030, the very factors fueling this growth—expanded production, complex global networks, and the patent cliff—are also creating a profound strategic vulnerability. The companies that win the next decade won’t just be those that scale, but those that build intelligent, transparent, and resilient global networks.

This document unpacks the hidden fault lines and strategic opportunities for Indian pharma leadership, exploring:

• The Carbon Amplified Value Chain: Why Scope 3 emissions represent the “elephant in the room” and constitute over 80% of a pharma company’s true footprint, growing invisibly with every new trade agreement and PLI-driven expansion.

• The $251 Billion Patent Cliff: How the loss of exclusivity for major branded drugs is resetting the competitive landscape, making efficiency, supplier collaboration, and proven ESG performance the decisive keys to capturing value in the post-patent generics and biosimilars market.

• From J&J to Your Boardroom: A stark look at how opaque supply chains are a repository of unquantified legal, social, and governance risk, using the Johnson & Johnson talc litigation as a definitive case study on how these failures erupt into catastrophic financial and reputational damage.

• Bridging the Ambition-Action Gap: A critical examination of why most net-zero commitments falter on Scope 3 execution and how leading companies are shifting from manual, spend-based estimations to precise, primary data for audit-ready reporting and strategic supplier partnerships.

For CXOs, supply chain leaders, and investors navigating this high-stakes environment, this is your roadmap to transforming sustainability from a compliance burden into your most powerful competitive advantage.

 [Download Here]